CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:CPH - CA17253X1050 - Common Stock
14.85 CAD
-0.38 (-2.5%)
CPH gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 32 industry peers in the Pharmaceuticals industry. CPH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: CPH is growing strongly while it also seems undervalued. This makes CPH very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year CPH was profitable.
In the past year CPH had a positive cash flow from operations.
CPH had positive earnings in each of the past 5 years.
Each year in the past 5 years CPH had a positive operating cash flow.
1.2 Ratios
CPH has a better Return On Assets (11.77%) than 96.88% of its industry peers.
CPH has a better Return On Equity (15.23%) than 87.50% of its industry peers.
CPH's Return On Invested Capital of 7.23% is amongst the best of the industry. CPH outperforms 90.63% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CPH is in line with the industry average of 7.90%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROIC | 7.23% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
1.3 Margins
CPH has a better Profit Margin (34.68%) than 100.00% of its industry peers.
In the last couple of years the Profit Margin of CPH has grown nicely.
With an excellent Operating Margin value of 25.51%, CPH belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
In the last couple of years the Operating Margin of CPH has declined.
The Gross Margin of CPH (74.32%) is better than 93.75% of its industry peers.
In the last couple of years the Gross Margin of CPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% |
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CPH is still creating some value.
CPH has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CPH has less shares outstanding
Compared to 1 year ago, CPH has a worse debt to assets ratio.
2.2 Solvency
CPH has an Altman-Z score of 6.34. This indicates that CPH is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.34, CPH belongs to the top of the industry, outperforming 93.75% of the companies in the same industry.
CPH has a debt to FCF ratio of 0.45. This is a very positive value and a sign of high solvency as it would only need 0.45 years to pay back of all of its debts.
The Debt to FCF ratio of CPH (0.45) is better than 90.63% of its industry peers.
A Debt/Equity ratio of 0.12 indicates that CPH is not too dependend on debt financing.
CPH's Debt to Equity ratio of 0.12 is fine compared to the rest of the industry. CPH outperforms 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Altman-Z | 6.34 |
ROIC/WACC0.9
WACC8.05%
2.3 Liquidity
CPH has a Current Ratio of 1.30. This is a normal value and indicates that CPH is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.30, CPH is doing worse than 62.50% of the companies in the same industry.
CPH has a Quick Ratio of 1.30. This is a bad value and indicates that CPH is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.98, CPH perfoms like the industry average, outperforming 40.63% of the companies in the same industry.
The current and quick ratio evaluation for CPH is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 |
3. Growth
3.1 Past
CPH shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.76%.
CPH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.97% yearly.
Looking at the last year, CPH shows a very strong growth in Revenue. The Revenue has grown by 89.17%.
Measured over the past years, CPH shows a quite strong growth in Revenue. The Revenue has been growing by 8.25% on average per year.
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
3.2 Future
CPH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.16% yearly.
The Revenue is expected to grow by 21.67% on average over the next years. This is a very strong growth
EPS Next Y38.33%
EPS Next 2Y19.46%
EPS Next 3Y13.16%
EPS Next 5YN/A
Revenue Next Year55.59%
Revenue Next 2Y30.55%
Revenue Next 3Y21.67%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 16.14, CPH is valued correctly.
Compared to the rest of the industry, the Price/Earnings ratio of CPH indicates a rather cheap valuation: CPH is cheaper than 81.25% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.11, CPH is valued a bit cheaper.
CPH is valuated correctly with a Price/Forward Earnings ratio of 16.20.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CPH indicates a somewhat cheap valuation: CPH is cheaper than 75.00% of the companies listed in the same industry.
CPH is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.21, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.14 | ||
| Fwd PE | 16.2 |
4.2 Price Multiples
CPH's Enterprise Value to EBITDA is on the same level as the industry average.
Based on the Price/Free Cash Flow ratio, CPH is valued a bit cheaper than the industry average as 78.13% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.02 | ||
| EV/EBITDA | 13.95 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CPH has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as CPH's earnings are expected to grow with 13.16% in the coming years.
PEG (NY)0.42
PEG (5Y)1.24
EPS Next 2Y19.46%
EPS Next 3Y13.16%
5. Dividend
5.1 Amount
No dividends for CPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:CPH (12/1/2025, 7:00:00 PM)
14.85
-0.38 (-2.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.35%
Inst Owner ChangeN/A
Ins Owners3.28%
Ins Owner ChangeN/A
Market Cap376.74M
Revenue(TTM)50.05M
Net Income(TTM)17.36M
Analysts77.5
Price Target18.39 (23.84%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.24%
Min EPS beat(2)36.14%
Max EPS beat(2)66.34%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-37.21%
Max EPS beat(4)66.34%
EPS beat(8)5
Avg EPS beat(8)34.73%
EPS beat(12)9
Avg EPS beat(12)113.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)-0.16%
Revenue beat(12)3
Avg Revenue beat(12)1.53%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)2.88%
PT rev (3m)2.88%
EPS NQ rev (1m)-6.06%
EPS NQ rev (3m)-6.06%
EPS NY rev (1m)0%
EPS NY rev (3m)-31.15%
Revenue NQ rev (1m)-6.28%
Revenue NQ rev (3m)-6.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.14 | ||
| Fwd PE | 16.2 | ||
| P/S | 5.39 | ||
| P/FCF | 9.02 | ||
| P/OCF | 9 | ||
| P/B | 2.37 | ||
| P/tB | 11.81 | ||
| EV/EBITDA | 13.95 |
EPS(TTM)0.92
EY6.2%
EPS(NY)0.92
Fwd EY6.17%
FCF(TTM)1.65
FCFY11.09%
OCF(TTM)1.65
OCFY11.12%
SpS2.75
BVpS6.27
TBVpS1.26
PEG (NY)0.42
PEG (5Y)1.24
Graham Number11.39
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROCE | 10.05% | ||
| ROIC | 7.23% | ||
| ROICexc | 7.75% | ||
| ROICexgc | 33.36% | ||
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% | ||
| FCFM | 59.76% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score7
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Debt/EBITDA | 0.67 | ||
| Cap/Depr | 1.2% | ||
| Cap/Sales | 0.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 152.24% | ||
| Profit Quality | 172.34% | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | 6.34 |
F-Score7
WACC8.05%
ROIC/WACC0.9
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
EPS Next Y38.33%
EPS Next 2Y19.46%
EPS Next 3Y13.16%
EPS Next 5YN/A
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
Revenue Next Year55.59%
Revenue Next 2Y30.55%
Revenue Next 3Y21.67%
Revenue Next 5YN/A
EBIT growth 1Y29.19%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year137.94%
EBIT Next 3Y37.97%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.32%
OCF growth 3Y12.28%
OCF growth 5Y19.77%
CIPHER PHARMACEUTICALS INC / CPH.CA FAQ
Can you provide the ChartMill fundamental rating for CIPHER PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA.
What is the valuation status of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
ChartMill assigns a valuation rating of 7 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Undervalued.
How profitable is CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.
How financially healthy is CIPHER PHARMACEUTICALS INC?
The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 7 / 10.